Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Seiji, Kawazoe"'
Autor:
Taiga Otsuka, Shunya Nakashita, Kimihiko Yanagita, Keisuke Ario, Hiroaki Kawasoe, Seiji Kawazoe, Yuichiro Eguchi, Toshihiko Mizuta
Publikováno v:
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who
Externí odkaz:
https://doaj.org/article/7915344b4090486b897d19ee9ffc3666
Autor:
Yukio Osaki, Seiji Kawazoe, Kazuhide Yamamoto, Mineo Kurokawa, Katsuaki Tanaka, Takahiro Fukuhara, Takayuki Katsube, Toshimitsu Ochiai, Masatoshi Kudo, Takeshi Kano, Michio Imawari, Hideyuki Tamai, Ryosuke Tateishi, Masataka Seike, Namiki Izumi
Publikováno v:
Journal of Gastroenterology
Background Thrombocytopenia represents an obstacle for invasive procedures in chronic liver disease (CLD) patients. We aimed to estimate the appropriate dose and evaluate the efficacy and safety of lusutrombopag for the treatment of thrombocytopenia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7126f1e021cedb7fb53559467a0bab9
https://doi.org/10.1007/s00535-018-1499-2
https://doi.org/10.1007/s00535-018-1499-2
Autor:
Taro Shibuki, Taiga Otsuka, Hiroshi Isoda, Norimasa Araki, Yoshihito Kubotsu, Yasunori Kawaguchi, Shunya Nakashita, Wataru Yoshioka, Seiji Kawazoe, Hiroaki Kawasoe, Yasushi Ide, Toshihiko Mizuta, Saga Study Group of Liver Diseases (SASLD)
Publikováno v:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
BACKGROUND It is important to avoid relapse in autoimmune hepatitis (AIH) because repeated multiple relapses have been associated with a worse prognosis. However, risk factors for relapse before initiation of treatment are not fully understood. The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e222f52f111df400218960ad4b4da312
https://doi.org/10.12659/msm.902576
https://doi.org/10.12659/msm.902576
Autor:
Takuji Okusaka, Madoka Takeuchi, Seiji Kawazoe, Masafumi Ikeda, Shinichi Ohkawa, Hisashi Hidaka, Hironori Tanaka, Yozo Sato, Shuichi Kaneko, Junji Furuse, Michihisa Moriguchi, Kazushi Numata, Xuemin Fang, Masatoshi Kudo, Yoshito Date, Masahiro Takeuchi
Publikováno v:
The Lancet Gastroenterology & Hepatology. 2:407-417
Summary Background Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07f7a53f246ca3815c98db9e015410c9
https://doi.org/10.1016/s2468-1253(17)30072-9
https://doi.org/10.1016/s2468-1253(17)30072-9
Autor:
Yoshiyuki Wada, Ryosuke Tateishi, Masafumi Ikeda, Etsuro Hatano, Hiroshi Ishii, Katsuaki Ukai, Andrew X. Zhu, Ling Yang, Sojiro Morita, Takuji Okusaka, Yukio Osaki, Shuichi Kaneko, Masatoshi Kudo, Hirofumi Fujii, Shuntaro Obi, Shinichi Ohkawa, Paolo Abada, Seiji Kawazoe, Osamu Yokosuka, Mitsuo Shimada, Akihito Tsuji, Gen Sugiyama, Toshihiro Kudo, Junji Furuse, Akihide Masumoto
Publikováno v:
Journal of Gastroenterology. 52:494-503
REACH evaluated ramucirumab in the second-line treatment of patients with advanced hepatocellular carcinoma. In the intent-to-treat population (n = 565), a significant improvement in overall survival (OS) was not observed. In patients with an elevate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9992901283fcae6c91ec7f7dd3d01dc
https://doi.org/10.1007/s00535-016-1247-4
https://doi.org/10.1007/s00535-016-1247-4
Autor:
Yuichiro Eguchi, Hiroaki Kawasoe, Seiji Kawazoe, Keisuke Ario, Shunya Nakashita, Taiga Otsuka, Kimihiko Yanagita, Toshihiko Mizuta
Publikováno v:
Diseases
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Volume 3
Issue 2
Pages 68-77
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Volume 3
Issue 2
Pages 68-77
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62b9f92161d11d98a5d646411a596ca
http://europepmc.org/articles/PMC5548234
http://europepmc.org/articles/PMC5548234
Autor:
Shinji Iwane, Yasushi Ide, Kimihiko Yanagita, Taiga Otsuka, Tsutomu Yasutake, Takanori Kumagai, Yuichiro Eguchi, Seiji Kawazoe, Takumi Akiyama, Toshihiko Mizuta, Yasunori Kawaguchi, Iwata Ozaki
Publikováno v:
Internal Medicine. 54:2551-2560
Objective This study evaluated the efficacy and safety of triple therapy with telaprevir (TVR), pegylated interferon α-2b (PegIFN-α-2b) and ribavirin (RBV) in Japanese patients chronically infected with hepatitis C virus (HCV) genotype 1b in real-w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a437ebbcfa2e718e5bcd513eab93109
https://doi.org/10.2169/internalmedicine.54.4817
https://doi.org/10.2169/internalmedicine.54.4817
Autor:
Florian Weissinger, Paolo Abada, Ling Yang, Baek Yeol Ryoo, Denis Pezet, Carlo Barone, Giovanni Brandi, Ari David Baron, Chung Pin Li, Jae Yong Cho, Shao Chun Chang, Joon Oh Park, Ian Chau, Kuan Der Lee, Takuji Okusaka, Masatoshi Kudo, Peter Malfertheiner, Chia Jui Yen, Hyun Cheol Chung, Andrew X. Zhu, Seiji Kawazoe, Yoshiyuki Wada
Importance REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6893935f616f2eee3ea1d5720a1fba0
http://hdl.handle.net/11585/566871
http://hdl.handle.net/11585/566871
Autor:
Kozo Kajimura, Isao Sakaida, Seiji Kawazoe, Takafumi Saito, Kiwamu Okita, Chiaki Okuse, Koichi Takaguchi, Mitsuru Okada
Publikováno v:
Hepatology Research. 44:73-82
Hepatic edema is manifested by ascites, lower limbedema and intolerable symptoms. Some patients insuffi-ciently respond to the conventional diuretic therapy. There-fore, a novel therapeutic option is required. We conducted aphase 3 study to confirm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e88359c695c3fe10d5b2b0584e588f93
https://doi.org/10.1111/hepr.12098
https://doi.org/10.1111/hepr.12098
Autor:
Mitsuru Okada, Kozo Kajimura, Kiwamu Okita, Chitomi Hasebe, Akira Kaneko, Seiji Kawazoe, Isao Sakaida
Publikováno v:
Hepatology Research. 44:83-91
Aim Liver cirrhosis represents the end stage of any chronic liver disease, and it is associated with hepatic edema such as ascites. Many patients with ascites do not respond to diuretic therapy or require administration of diuretics at high doses tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ede34def07317f4fd92d8ed050405a8b
https://doi.org/10.1111/hepr.12099
https://doi.org/10.1111/hepr.12099